We read with great interest the article by Chi et al. investigating the effect of inhibiting mammalian target of rapamycin (mTOR) with a third generation mTOR inhibitor, Rapalink-1, in an experimental model of stroke (Chi et al., 2021). Here, MTOR is linked to stroke disorder.